Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Huperzine A wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Likely helps
4 of 5 studies with measurable effects showed benefit.
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (3)
Outcomes where both Huperzine A and Noopept have evidence — compare verdict strength side-by-side.
50-200mcg twice daily
Morning and early afternoon, Avoid evening (may cause vivid dreams)
Huperzine A capsules (standardized extract)
10-30mg daily in divided doses
Morning and early afternoon, Divided into 2-3 doses, Sublingual for faster onset
Noopept powder (sublingual) or capsules
2-4 weeks
30-60 minutes
2-4 weeks
During use
1-2 weeks
Acute to 1 week
Ongoing
With higher doses
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Traditional Chinese herbal medicine for vascular dementia
The Cochrane database of systematic reviews (2018) · Systematic review · n=3581
Two TCHMs (NaoMaiTai and TongXinLuo) had a 5% or more increased risk of AEs compared to the 'no Treatment' control, but the quality of this evidence was poor.
Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews
BMJ open (2016) · Systematic review · n=289
The quality of the reviews varied; however most (65%) scored 8/11 or more on the AMSTAR tool, indicating high quality.
Novel Technologies for Dipeptide Drugs Design and their Implantation
Current pharmaceutical design (2018) · Systematic review
The latter usually corresponds to a beta-turn of some regulatory peptide.
Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation
Journal of biomedical science (2014) · Observational
Taken together, these data provide evidence that novel cognitive enhancer noopept protects PC12 cell against deleterious actions of Aβ through inhibiting the oxidative damage and calcium overload as well as suppressing the mitochondrial apoptotic pathway.
Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin
Neuroscience and behavioral physiology (2009) · Observational
Clinical trial examining Noopept efficacy
Based on meta-analysis showing MMSE improvement (WMD: 2.27) in dementia populations. Evidence primarily from dementia patients, limited data in healthy individuals. Quality concerns noted in systematic reviews regarding study methodology.
Based on RCT with n=60 showing MMSE improvements after 2 months. Most studies lack placebo controls and have small sample sizes. Effectiveness may be overestimated due to study limitations.
AI-estimated from published studies. Interpret as directional guidance.
Huperzine A has a higher evidence score (6/10 vs 4/10) and wins in 2 of 3 categories.
For sharpen focus, Huperzine A has a higher relevance score (80 vs 75).
No known interactions between Huperzine A and Noopept have been documented in our database. However, always consult a healthcare provider before combining supplements.